Synergy between mecillinam and ceftazidime/avibactam or avibactam against multi-drug-resistant carbapenemase-producing escherichia coli and klebsiella pneumoniae

HIGHLIGHTS

  • who: Karoline Knudsen List and collaborators from the Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen have published the Article: Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae, in the Journal: Antibiotics 2022, 1280 of /2022/
  • what: The aim of the study was to evaluate the efficacy of mecillinam in combination with either avibactam or ceftazidime/avibactam against 18 carbapenemase-producing MDR clinical isolates of K. pneumoniae and E. coli, in_vitro and in_vivo.
  •  

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?